Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of Garsorasib in Healthy Chinese Men
NCT06233916Phase 1Completed
- Sponsor
- InventisBio
- Start
- Dec 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of garsorasib in non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC), sponsored by InventisBio. Primary endpoints: Total Radioactivity Recovery at 2 weeks, Percentage of unchanged drug and metabolites at 2 weeks and 6 more. Started Dec 2023; status: completed.
02
Drugs
garsorasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06233916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233916.